Please Note: The venue has changed from that which was previously advertised. See Here.
Europe’s Largest Industry-Led & Dedicated Gathering for mRNA Professionals
The eagerly anticipated mRNA-Based Therapeutics Summit Europe returns to Berlin this January for the third year as Europe’s largest and most important gathering of mRNA experts.
Showcasing exclusive new data from the trailblazers and thought leaders in the field, join 200+ industry specialists including the likes of the MHRA, EMA, BioNTech, CureVac, Ziphius Vaccines, Moderna and more across 3 days to uncover groundbreaking discovery, pre-clinical and clinical insights in mRNA therapeutic and vaccine development to fast-track R&D and pipeline expansions.
Key Themes for 2024:
Unlock European-specific regulatory expectations for mRNA therapeutics and vaccines to ensure compliance, identify potential risks and enable patient access to your drugs without delays
Overcome safety, PK/PD and translational hurdles to accelerate a surge of pre-clinical mRNA-based therapeutic candidates into robust clinical pipelines with emphasis on improving the efficiency and success of your drugs
Improve drug delivery vehicle design and molecule characterisation to overcome immunogenicity and thermostability hurdles
Maintain momentum in mRNA mergers and acquisitions, partnerships and investments in Europe and beyond to fuel the next generation of breakthroughs, reduce cost of goods and ensure R&D success beyond COVID-19
- Unlock European-specific regulatory expectations for mRNA therapeutics and vaccines to ensure compliance, identify potential risks and enable patient access to your drugs without delays
- Overcome safety, PK/PD and translational hurdles to accelerate a surge of pre-clinical mRNA-based therapeutic candidates into robust clinical pipelines with emphasis on improving the efficiency and success of your drugs
- Improve drug delivery vehicle design and molecule characterisation to overcome immunogenicity and thermostability hurdles
- Maintain momentum in mRNA mergers and acquisitions, partnerships and investments in Europe and beyond to fuel the next generation of breakthroughs, reduce cost of goods and ensure R&D success beyond COVID-19
“I look forward to connecting with other experts from the field and gather valuable insight into how typical and specific challenges in the mRNA field may be overcome”
Claudia Lindemann
Director – Non-Clinical Safety, BioNTech SE
Among Our 50+ World-Class Speaker Faculty
“This is a great opportunity to network, and to hear from other experts about what the current bottlenecks and opportunities are, what areas of mRNA therapeutics platform require further development and how to generate compelling data packages to address gaps”
Sam Deutsch
EVP – Research & Early Development, Nutcracker Therapeutics
Who’s Attending in January?
“I see first-hand at how this meeting is a great opportunity for discussing the most recent findings in the mRNA therapeutics field with colleagues in the field”
Camilla Foged
Professor - Vaccine Design & Delivery, University of Copenhagen
Official Partners
Lead Partner
Industry Partner
“The 3rd mRNA-Based Therapeutics Summit Europe provides a stimulating environment to connect and interact with experts in this fast-growing field, and to exchange thoughts and ideas that may shape the future of mRNA therapeutics”
Jenny van Asbeck-van der Wijst
CEO, Mercurna
